Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present findings provide evidence that LDR-induced PAX8 acts as an important regulator for suppression of thyroid carcinogenesis through novel STAT3/miR-330-5p pathway in thyroid cancers.
|
30760304 |
2019 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
A PAX8-PPARγ fusion protein (PPFP) is oncogenic in a subset of thyroid cancers, suggesting that inhibition of endogenous PPARγ function by the fusion protein could contribute to thyroid oncogenesis.
|
29420754 |
2018 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer.
|
28008156 |
2017 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some somatic oncogene mutations (BRAF, NRAS, HRAS, KRAS) as well as gene translocations (RET/PTC, PAX8/PPAR-gamma) have been associated with the development of thyroid cancer.
|
26259532 |
2016 |
Malignant neoplasm of thyroid
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PAX8 is a thyroid-specific transcription factor whose expression is dysregulated in thyroid cancer.
|
27249794 |
2016 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall.
|
24811481 |
2014 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
TSH receptor mRNA reverse transcription-polymerase chain reaction, the Veracyte and Asuragen commercial methods, and the noncommercial use of BRAF, RAS, RET/PTC, and PAX8/PPARγ testing have promising roles in the diagnosis and treatment of patients with nodular thyroid disease and thyroid cancer.
|
22984796 |
2013 |
Malignant neoplasm of thyroid
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared to normal tissues, NIS and PAX8 mRNA levels were significantly reduced in all types of thyroid cancer.
|
22510021 |
2012 |
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this review, we will summarize the histologic features of known recurrent genomic rearrangements in carcinomas, especially focusing on TMPRSS2-ERG fusion in prostate cancer, EML4-ALK in lung cancer, ETV6-NTRK3 in secretory breast cancer, RET/PTC and PAX8/PPARγ1 rearrangements in thyroid cancer.
|
23060067 |
2012 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that Pax-8 can promote iodide uptake, and specifically prolong the retention time of iodide in thyroid cancer in vitro and in vivo by promoting the expression of TPO and Tg proteins.
|
21833035 |
2012 |
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements.
|
21878896 |
2011 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Follicular thyroid cancers harbor translocations and fusions of certain genes (PAX 8 and PPAR-gamma).
|
20578236 |
2010 |
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs).
|
19147628 |
2009 |
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As such, this article addresses the following aspects of intragenic mutations in thyroid cancer: thyroid stimulating hormone receptor and guanine-nucleotide-binding proteins of the stimulatory family mutations in hyperfunctioning tumors; mutations in RAS and other genes and aneuploidy; PAX8-PPARgamma rearrangements; BRAF mutations; mutations in oxidative phosphorylation and Krebs cycle genes in Hürthle cell tumors; mutations in succinate dehydrogenase genes in medullary carcinoma and C-cell hyperplasia; and mutations in TP53 and other genes in poorly differentiated and anaplastic carcinomas.
|
18502330 |
2008 |
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PPARgamma may play a role in thyroid carcinogenesis since PAX8-PPARgamma1 chromosomal translocations are commonly found in follicular thyroid cancers.
|
15785241 |
2005 |
Malignant neoplasm of thyroid
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because of the more favorable prognosis for PTC in children compared to young patients, we hypothesized that Pax-8 expression might be different in pediatric thyroid cancers.
|
15650356 |
2004 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cotransduction of AdTTF-1 and AdTGTK permitted 90% cytotoxicity for BHP15-3 and >95% cytotoxicity for FRT, as well as for BHP7-13 and BHP18-21v thyroid cancer cell lines [both/TTF1(-)/TTF-2(-)/Pax-8(+)/TG(-)].
|
11325833 |
2001 |
Malignant neoplasm of thyroid
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To correlate the differentiation phenotype of two human thyroid cancer cell lines with their expression of various molecular markers, we analyzed the mRNA levels of four thyroid-specific genes, including thyrotropin receptor (TSHR), thyroglobulin (Tg), thyroid transcription factor-1 (TTF-1), and paired-box containing transcription factor-8 (PAX-8) genes.
|
10810302 |
2000 |